Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-BACE Combined With Sintilimab in Stage II/III NSCLC
NCT05248022Not yet recruiting
- Sponsor
- Lishui City Central Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
01
Overview
Randomised, open-label trial of sintilimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Lishui City Central Hospital. Primary endpoint: Progression Free Survival at 2 years. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05248022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248022.